PPA
SUPN icon

Parametric Portfolio Associates’s Supernus Pharmaceuticals SUPN Stock Holding History

Parametric Portfolio Associates’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$7.27M Sell
224,892
-7,806
-3% -$239K ﹤0.01% 1589
2021
Q4 		$6.79M Buy
232,698
+59,141
+34% +$1.79M ﹤0.01% 1655
2021
Q3 		$4.63M Buy
173,557
+24,873
+17% +$668K ﹤0.01% 1881
2021
Q2 		$4.58M Sell
148,684
-8,908
-6% -$273K ﹤0.01% 1900
2021
Q1 		$4.13M Sell
157,592
-15,644
-9% -$438K ﹤0.01% 2308
2020
Q4 		$4.36M Buy
173,236
+23,648
+16% +$509K ﹤0.01% 2158
2020
Q3 		$3.12M Buy
149,588
+7,401
+5% +$168K ﹤0.01% 2220
2020
Q2 		$3.38M Buy
142,187
+56,118
+65% +$1.24M ﹤0.01% 2149
2020
Q1 		$1.55M Sell
86,069
-29,223
-25% -$614K ﹤0.01% 2540
2019
Q4 		$2.73M Sell
115,292
-40,480
-26% -$983K ﹤0.01% 2482
2019
Q3 		$4.28M Sell
155,772
-5,012
-3% -$149K ﹤0.01% 2126
2019
Q2 		$5.32M Sell
160,784
-45,937
-22% -$1.57M ﹤0.01% 1968
2019
Q1 		$7.24M Sell
206,721
-71,896
-26% -$2.68M 0.01% 1675
2018
Q4 		$9.26M Sell
278,617
-60,426
-18% -$2.6M 0.01% 1388
2018
Q3 		$17.1M Sell
339,043
-60,691
-15% -$3M 0.01% 1008
2018
Q2 		$23.9M Buy
399,734
+19,903
+5% +$1.03M 0.02% 733
2018
Q1 		$17.4M Buy
379,831
+71,442
+23% +$2.98M 0.02% 914
2017
Q4 		$12.3M Sell
308,389
-27,458
-8% -$1.09M 0.01% 1164
2017
Q3 		$13.4M Buy
335,847
+28,716
+9% +$1.24M 0.01% 1006
2017
Q2 		$13.2M Buy
307,131
+28,446
+10% +$1.01M 0.02% 970
2017
Q1 		$8.72M Buy
278,685
+26,417
+10% +$708K 0.01% 1258
2016
Q4 		$6.37M Buy
252,268
+32,626
+15% +$729K 0.01% 1453
2016
Q3 		$5.43M Sell
219,642
-1,854
-0.8% -$42K 0.01% 1492
2016
Q2 		$4.51M Buy
221,496
+28,875
+15% +$512K 0.01% 1628
2016
Q1 		$2.94M Buy
192,621
+154,929
+411% +$2.02M ﹤0.01% 2073
2015
Q4 		$507K Buy
37,692
+226
+0.6% +$3.5K ﹤0.01% 3237
2015
Q3 		$526K Buy
37,466
+10,864
+41% +$202K ﹤0.01% 2695
2015
Q2 		$452K Buy
+26,602
New +$379K ﹤0.01% 3345

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parametric Portfolio Associates's SUPN Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Supernus Pharmaceuticals (SUPN) stake by 3.4% in Q1 2022, selling an estimated $239K and leaving 224,892 shares worth $7.27M. The position accounts for ﹤0.01% of the portfolio, ranked #1589.

Parametric Portfolio Associates first reported a position in SUPN in Q2 2015 and has held it in 28 quarters since. The position peaked at $23.9M in Q2 2018. 230 funds tracked by Wall St. Rank hold SUPN as of Q1 2022.

  • Parametric Portfolio Associates held 224,892 shares of Supernus Pharmaceuticals worth $7.27M as of Q1 2022.
  • Parametric Portfolio Associates sold 7,806 Supernus Pharmaceuticals shares in Q1 2022, an estimated $239K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1589 holding.
  • Parametric Portfolio Associates first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 28 quarters since.
  • Parametric Portfolio Associates's Supernus Pharmaceuticals position peaked at $23.9M in Q2 2018.
  • 230 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.